▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3079 by analyst upside · 2026-11-12
CLOV
Clover Health Investments, Corp.
Healthcare · Market Cap $3B · P/E 497.0x
ANALYST PRICE TARGET
+12.7%
implied upside to consensus target
Current Price $4.97
Consensus Target $5.6
Bull Target $6.0
Bear Target $5.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
2
Hold
2
Sell
0
52-Week Low $1.58
52-Week High $5.59
YTD Return +106.2%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) 497.0x
Forward P/E 27.6x
EPS (TTM) $0.01
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $2.7B
Profit Margin 0.5%
52-WEEK RANGE
52-Week Low $1.58
52-Week High $5.59
Current Price $4.97
Bear Target $5.0
Bull Target $6.0
● Now $4.97 ● Target $5.6
TRADING DATA
Avg Volume 4.3M
YTD Return +106.2%
Analyst Count 5
Consensus Buy
Upside to Target +12.7%
Last Updated 2026-11-12

ANALYST SUMMARY

Clover Health Investments, Corp. (CLOV) is currently trading at $4.97 with a Wall Street consensus price target of $5.6, implying potential upside of 12.7% over the next 12 months. 5 analysts currently cover CLOV, with a consensus rating of Buy - 60% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $6.0, while the most cautious has a target of $5.0.

CLOV operates in the Healthcare sector with a market capitalisation of $3B. The stock is up 106.2% year-to-date and is currently trading near the upper end of its 52-week range of $1.58 – $5.59.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CLOV, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Neutral → Neutral 2026-11-06 33% win rate (6 calls)
Needham ● Initiated
Buy 2026-10-28 20% win rate (5 calls)
UBS - Reiterated
Neutral → Neutral 2026-08-06 33% win rate (6 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-07-21 Building track record
UBS - Reiterated
Neutral → Neutral 2026-06-11 33% win rate (6 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-06-04 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-03-20 Building track record
Leerink Partners - Reiterated
Market Perform → Market Perform 2026-03-05 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
54
out of 100
Coverage depth
14/30
Consensus clarity
26/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →